83673
document
Interactive effects of indomethacin , angiotensin II and frusemide on renal haemodynamics and natriuresis in man . The responses of renal haemodynamic and natriuretic indices to the oral prostaglandin synthetase inhibitor indomethacin ( 200 mg ) , to infused angiotensin II ( 1 ng min-1 kg-1 ) and to the combination of the two were studies in placebo-controlled fashion in eight normal male subjects both prior to and following administration of intravenous frusemide ( 20 mg ) . As compared with placebo , angiotensin II infusion alone caused significant reductions in absolute rate of sodium excretion , fractional sodium excretion , urine flow rate and effective renal plasma flow ( all P < 0.001 vs placebo ) but had no effect on glomerular filtration rate . The only change observed in these parameters with indomethacin alone was a small but significant reduction in urine flow rate ( P < 0.005 vs placebo ) . As compared with the effects of angiotensin II alone , indomethacin pre-treatment followed by angiotensin II infusion led to much greater falls in absolute rate of sodium excretion , fractional sodium excretion , urine flow rate and effective renal plasma flow ( all P < 0.0001 vs placebo ) associated with a significant reduction in glomerular filtration rate ( P < 0.0001 ) not observed with angiotensin II alone . Frusemide administration at the midpoint of each study limb resulted in each case in a prompt 15 to 20 fold increase in natriuresis . The renal haemodynamic and natriuretic effects of angiotensin II , indomethacin and their combination were not qualitatively different from those observed in the pre-frusemide phase . Our findings provide a clear demonstration in man of the important homeostatic role of renal prostaglandins in preserving renal function , particularly glomerular filtration , under conditions of elevated circulating angiotensin II .
83674
Intervention_Pharmacological
indomethacin
83675
Intervention_Pharmacological
angiotensin II
83676
Intervention_Pharmacological
frusemide
83677
Intervention_Pharmacological
indomethacin ( 200 mg )
83678
Intervention_Pharmacological
infused angiotensin II
83679
Intervention_Control
placebo-controlled
83680
Intervention_Pharmacological
intravenous frusemide
83681
Intervention_Control
placebo
83682
Intervention_Pharmacological
angiotensin II infusion
83683
Intervention_Pharmacological
indomethacin
83684
Intervention_Pharmacological
indomethacin
83685
Intervention_Pharmacological
angiotensin II
83686
Intervention_Control
placebo
83687
Intervention_Pharmacological
Frusemide
83688
Intervention_Pharmacological
pre-frusemide
83689
Outcome_Physical
absolute rate of sodium excretion
83690
Outcome_Physical
fractional sodium excretion
83691
Outcome_Physical
urine flow rate
83692
Outcome_Physical
effective renal plasma flow
83693
Outcome_Physical
glomerular filtration rate
83694
Outcome_Physical
urine flow rate
83695
Outcome_Physical
absolute rate of sodium excretion
83696
Outcome_Physical
fractional sodium excretion
83697
Outcome_Physical
urine flow rate
83698
Outcome_Physical
effective renal plasma flow
83699
Outcome_Physical
glomerular filtration rate
83700
Outcome_Physical
natriuresis
83701
Outcome_Physical
renal haemodynamic and natriuretic effects
83702
Outcome_Physical
homeostatic role
83703
Outcome_Physical
renal function , particularly glomerular filtration
83704
Participant_Condition
eight
83705
Participant_Condition
male